FDA to review use of asthma drugs in children

Share this article:

The FDA is recommending an additional safety review of  GlaxoSmithKline's Serevent and Advair and Novartis' Foradil in children.

An advisory panel of pediatricians is scheduled to discuss side effects of the asthma medications at a meeting on Nov. 27.

The FDA strengthened warning labels for the drugs nearly two years ago to limit use to patients who don't benefit from other medications.

“There is no available pediatric data to indicate that the increased risk of asthma death and life-threatening exacerbations observed in adults does not also apply to children,” the FDA wrote in a report posted on its Web site.

The review didn't identify any adverse reactions unique to children but did imply that Serevent may have more risks than benefits for young users. 

Global sales for Serevent and Advair rose 12% to $6.13 billion in 2006, making them the second best-selling medicines behind Pfizer's $12 billion-seller, the cholesterol drug Lipitor.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.